Patents by Inventor Ralph Mazitschek

Ralph Mazitschek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Photoswitchable HDAC Inhibitors
    Publication number: 20210162048
    Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 3, 2021
    Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 10968180
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 6, 2021
    Assignee: Regenacy Pharmaceuticals, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • ANALOGS OF CELASTROL
    Publication number: 20210061851
    Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
    Type: Application
    Filed: April 15, 2020
    Publication date: March 4, 2021
    Inventors: Ralph Mazitschek, Yanbing Ding, Kaisheng Shen
  • Phenyl and pyridinyl hydroxamic acids
    Patent number: 10927072
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: February 23, 2021
    Assignee: ACETYLON PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • COMPOUNDS FOR THE TREATMENT OF OBESITY AND METHODS OF USE THEREOF
    Publication number: 20210008019
    Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
    Type: Application
    Filed: April 28, 2020
    Publication date: January 14, 2021
    Inventors: Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
  • SUBSTITUTED PIPERAZINES AS SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20200377465
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: August 19, 2020
    Publication date: December 3, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Photoswitchable HDAC inhibitors
    Patent number: 10828367
    Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 10, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Balaram Ghosh, James Adam Hendricks, Surya Reis, Stephen John Haggarty
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 10774056
    Abstract: Provided herein are substituted piperazine compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 15, 2020
    Assignee: REGENACY PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • BODIPY dyes for biological imaging
    Patent number: 10696695
    Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 30, 2020
    Assignee: The General Hospital Corporation
    Inventors: Ralph Mazitschek, Alexandra M. Courtis, James Adam Hendricks
  • Analogs of celastrol
    Patent number: 10662218
    Abstract: Described herein, inter alia, are compositions and methods for treating or preventing obesity and using the same.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: May 26, 2020
    Inventors: Ralph Mazitschek, Yanbing Ding, Kaisheng Shen
  • Compounds for the treatment of obesity and methods of use thereof
    Patent number: 10653654
    Abstract: Pentacyclic triterpene weight loss agents are provided herein. Also provided are pharmaceutical formulations containing a therapeutically effective amount of one or more of the weight loss agents, or pharmaceutically acceptable salts or prodrugs thereof, in combination with one or more pharmaceutically acceptable excipients. The pharmaceutical formulations can be administered to a pre-obese, obese, or morbidly obese patient to induce weight loss, reduce body fat, reduce food intake, improve glucose homeostasis, prevent obesity, or a combination thereof. The weight loss agents can also be co-administered with leptin or a leptin analog.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 19, 2020
    Assignees: The Children's Medical Center Corporation, The General Hospital Corporation
    Inventors: Umut Ozcan, Joseph Majzoub, Ralph Mazitschek
  • Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof
    Publication number: 20200030325
    Abstract: The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.
    Type: Application
    Filed: August 26, 2019
    Publication date: January 30, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek, Walter Olgier, James E. Bradner, Guoxiang Huang, Dejian Xie, Nan Yu
  • PHENYL AND PYRIDINYL HYDROXAMIC ACIDS
    Publication number: 20200010407
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Application
    Filed: July 19, 2019
    Publication date: January 9, 2020
    Inventors: John H. van Duzer, Ralph Mazitschek
  • PIPERIDINE DERIVATIVES AS HDAC1/2 INHIBITORS
    Publication number: 20190359569
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: June 6, 2019
    Publication date: November 28, 2019
    Inventors: John H. van Duzer, Ralph Mazitschek
  • SELECTIVE HDAC1,2 INHIBITORS
    Publication number: 20190330169
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Application
    Filed: July 10, 2019
    Publication date: October 31, 2019
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Substituted piperazines as selective HDAC1,2 inhibitors
    Patent number: 10385031
    Abstract: Provided herein are compounds of Formula II, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 20, 2019
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Phenyl and pyridinyl hydroxamic acids
    Patent number: 10370324
    Abstract: The present invention relates to pyrimidine hydroxy amide compounds, the use of such compounds in the inhibition of HDAC6, and the use of such compounds in the treatment of various diseases, disorders, or conditions related to HDAC6.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: August 6, 2019
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 10358421
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: July 23, 2019
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek
  • BODIPY DYES FOR BIOLOGICAL IMAGING
    Publication number: 20190127394
    Abstract: This invention relates to water-soluble mono-alkoxy and mono-alkyne BODIPY derivatives, including methods for making the same. For examples, provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: is a BODIPY ligand system; X is a halogen; L is absent or a linker; and Z is selected from the group consisting of: a group reactive with a biologically active molecule and a detectable agent.
    Type: Application
    Filed: June 25, 2018
    Publication date: May 2, 2019
    Inventors: Ralph Mazitschek, Alexandra M. Courtis, James Adam Hendricks
  • Piperidine derivatives as HDAC1/2 inhibitors
    Patent number: 10239837
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 26, 2019
    Assignee: REGENACY PHARMACEUTICALS, LLC
    Inventors: John H. van Duzer, Ralph Mazitschek